Related coverage linked through entity extraction aliases.
Feb 14, 2026
Alvotech announced successful clinical trial results for AVT80, a biosimilar to Takeda's Entyvio, meeting all primary endpoints. The company targets a $6.4 billion market opportunity with regulatory submissions planned.
Feb 14, 2026
Bristol-Myers Squibb received orphan drug designation from the FDA on Feb. 13 for a treatment targeting follicular lymphoma, a type of cancer affecting the lymphatic system.
Feb 14, 2026
Syndax Pharmaceuticals partnered with World Orphan Drug Alliance to launch a Managed Access Program for Revuforj in multiple regions. A price target was raised to $28 while maintaining a Buy rating.
Feb 14, 2026
A newly published study in Int. J. Mol. Sci. confirms that deuterium concentration directly influences gene expression in lung adenocarcinoma cells, validating HYD LLC's three-decade research on deuterium-depleted water as a complementary cancer therapy.
Feb 14, 2026
Pharmaceutical companies are deploying AI and machine learning across clinical trial execution, regulatory submissions, and drug discovery to address rising costs and lengthy timelines in drug development.
Feb 13, 2026
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
Feb 12, 2026
Trethera Corporation completed Phase 1 solid tumor dose escalation trial for TRE-515 and received FDA Fast Track designation for prostate cancer and Orphan Drug status for two autoimmune neurologic diseases.
Feb 13, 2026
A case report published in Oncotarget details a 38-year-old woman who developed acute lymphoblastic leukemia and lymphoblastic lymphoma shortly after receiving her second Pfizer-BioNTech mRNA vaccine dose, prompting calls for further investigation into potential immune-related mechanisms.
Feb 13, 2026
Moderna reported Q4 revenue of $678 million, beating analyst estimates, while posting a narrower-than-expected loss of $2.11 per share. The results came as the FDA refused to review the company's mRNA flu vaccine application.
Feb 13, 2026
Immunotherapy is increasingly being used before and after surgery across seven cancer types, while the global immunotherapy drugs market experiences significant growth driven by advances in biotechnology and targeted therapies.
Feb 13, 2026
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Feb 13, 2026
NeoGenomics has introduced PanTracer Pro, a molecular testing solution combining comprehensive genomic profiling with diagnosis-directed assays for advanced solid tumors, designed to streamline biomarker assessment and support faster treatment decisions.
Feb 12, 2026
Merck KGaA has entered a partnership with Calla Lily Clinical Care to advance Callavid, an intravaginal drug delivery platform designed to address patient challenges in women's health therapeutics, with initial focus on fertility and pregnancy applications.
Feb 13, 2026
Merck stock reached a 52-week high at $122.69, rising 46.25% over 12 months and 7.4% in the past month following strong Q4 results and improved long-term pipeline outlook beyond Keytruda's 2028 patent expiration.
Feb 13, 2026
HCW Biologics and WY Biotech closed first-round financing for joint venture Trimmune, granting exclusive worldwide license to develop preclinical TRBC molecule HCW11-006 for $7 million in upfront consideration, with Phase 1 trial planned in China for first half of 2027.
Feb 12, 2026
Researchers have developed a highly sensitive light-based sensor combining DNA nanostructures, quantum dots, and CRISPR technology to detect cancer biomarkers at sub-attomolar levels in blood samples.
Feb 13, 2026
Global pharmaceutical companies are accelerating licensing deals for China-developed experimental medicines, with deal values reaching unprecedented levels in 2026 as firms cut costs ahead of patent expirations.
Feb 13, 2026
China now leads globally with 624 Phase 3 cancer trials, representing 48.5% of the total, while its share of global drug development has risen to 20% with investigational new drugs accounting for 30% of the world's pipeline.
Feb 13, 2026
Lunai Bioworks was featured on CNBC on February 13, 2026, showcasing its AI platform for CNS therapeutics and biodefense. The company reported improved financial performance with net income of $1.02 million compared to a $51.46 million loss the previous year.
